Oxford BioTherapeutics hires chairman
pharmafile | June 27, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Oxford Biotherapeutics, morton
Biotech firm Oxford BioTherapeutics has appointed Bryan Morton to be the company’s new non-executive chairman.
Morton has over 30 years’ experience as an entrepreneur and senior manager in the pharma industry. He was previously chief executive of EUSA Pharma, a global speciality oncology company, which was acquired by Jazz Pharmaceuticals in 2012 for $700 million.
After founding EUSA in 2005, Morton was able to fund the company’s growth by raising $265 million from several prominent life science investors, including Goldman Sachs, Essex Woodland, 3i, Advent, SV Life Sciences, Neomed and Novaquest.
In 2003 Morton founded and was appointed chief executive of Zeneus Pharma, a European speciality oncology and critical care company. Prior to running Zeneus, Morton was president of Convatec, EMEA (Bristol-Myers Squibb) and spent over 20 years in positions of increasing responsibility at Merck.
Christian Rohlff, chief executive and founder of OBT said: “I am delighted that Bryan has decided to accept the position of chairman at OBT. His success in building valuable businesses and knowledge of the cancer space in particular will be important as we look to further develop our pipeline of antibody based cancer medicines to fulfil unmet patient needs. I would like to take this opportunity to thank Dr Michael Moore for his wise counsel and support over the last three and a half years.
Morton added: “I am glad to have this opportunity to work with Christian and the team at OBT. I am looking forward to using my experience in building successful speciality pharma businesses to allow me to make an important contribution to OBT as it enters the next phase of its corporate development.”
Related Content
Tech platform company WuXi Biologics inks deal with cancer specialist Oxford BioTherapeutics worth $450m
Clinical stage oncology firm Oxford BioTherapeutics has signed a deal with the open-access biologics technology …
Sanofi buys into cancer antibody research
Sanofi-Aventis has bought a global licence to develop and commercialise one of Oxford BioTherapeutics’ (OBT) …
GSK signs oncology deal with UK biotech
GSK has struck a deal with Oxford BioTherapeutics to develop therapies for primary, metastatic and …
